Earnings Per Common Share - Additional Information (Details) - shares
|
1 Months Ended |
12 Months Ended |
Nov. 30, 2019 |
Dec. 31, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
|
|
|
| Weighted-average incremental shares from forward equity sales agreements (in shares) |
|
|
2,771,000
|
0
|
0
|
| Convertible Units |
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
|
|
|
| Antidilutive securities excluded from computation of earnings per share (in shares) |
|
|
28,000,000
|
15,000,000
|
|
| Down R E I T [Member] |
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
|
|
|
| Antidilutive securities excluded from computation of earnings per share (in shares) |
|
|
7,000,000
|
2,000,000
|
7,000,000
|
| Common Stock Options |
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
|
|
|
| Antidilutive securities excluded from computation of earnings per share (in shares) |
|
|
1,000,000
|
1,000,000
|
1,000,000
|
| 2019 ATM Program |
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
|
|
|
| Maximum shares issuable under forward equity sales agreement (in shares) |
|
|
20,300,000
|
|
|
| Settlement alternatives, fair value (in shares) |
|
|
5,500,000
|
|
|
| Forward contract, outstanding (in shares) |
|
|
14,800,000
|
|
|
| Forward Equity Offering |
|
|
|
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
|
|
|
| Maximum shares issuable under forward equity sales agreement (in shares) |
15,600,000
|
15,300,000
|
15,300,000
|
|
|
| Issuance of common stock, net (in shares) |
|
0
|
15,300,000
|
|
|
| Forward contract, outstanding (in shares) |
|
|
15,600,000
|
|
|